The Oncology Institute, Inc.

As of May 10, 2023, The Oncology Institute, Inc. has shifted from an attractive to a risky valuation grade due to severe inefficiencies reflected in its negative financial ratios, indicating it is overvalued despite a significant year-to-date stock return of 948.54%.

As of May 10, 2023, The Oncology Institute, Inc. is considered overvalued and risky due to its negative P/E ratio, extremely high Price to Book Value of 48.83, and alarming ROE of -1040.97%, despite a significant YTD return of 641.10%.

As of June 9, 2025, the trend is mildly bullish due to daily moving averages and Bollinger Bands, but caution is advised because weekly MACD and KST are mildly bearish and RSI shows no momentum confirmation.

The Oncology Institute, Inc. operates in the Pharmaceuticals & Biotechnology sector, focusing on healthcare-related business combinations, with recent net sales of $104 million and a net loss of $16 million. The company has a market cap of $215.08 million and key metrics indicating significant financial challenges.

As of Jun 18, The Oncology Institute, Inc. has a market capitalization of 215.08 million, with net sales of 403.16 million and a net profit of -52.80 million over the last four quarters. Shareholder's funds are reported at 3.59 million, and total assets amount to 181.91 million.